Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 17/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915097 | 1.00 | NT5E (0.73) | NT5EADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL24618960 | 0.98 | NT5E (0.70) | NT5E | |
| SCHEMBL19366711 | 0.91 | NT5E (0.71) | NT5EADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL24619126 | 0.88 | NT5E (0.59) | NT5E | |
| SCHEMBL24618924 | 0.88 | NT5E (0.58) | NT5E | |
| SCHEMBL30008238 | 0.87 | NT5E (0.59) | NT5E | |
| SCHEMBL24619067 | 0.86 | NT5E (0.56) | NT5EADORA2A | |
| SCHEMBL20168539 | 0.85 | NT5E (0.64) | NT5E | |
| SCHEMBL27210210 | 0.85 | NT5E (0.73) | NT5E | |
| SCHEMBL22614572 | 0.84 | NT5E (1.00) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11807658-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220220147-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-07-14 | — | — | US | disclosed |
| US-11325938-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ARCUS BIOSCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210371449-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20200222441-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200062797-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ARCUS BIOSCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
| EP-3600273-A1 | CD73 INHIBITORS AND USES THEREOF | Peloton Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| WO-2018183635-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018094148-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ARCUS BIOSCIENCES, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885ADORA3 29/4885ADORA2A 11/4885 |
| US-11807658-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 19/4885ADORA2A 11/4885 |
| US-20220220147-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 19/4885ADORA2A 11/4885 |
| US-11325938-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 19/4885ADORA2A 11/4885 |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885ADORA3 35/4885ADORA2A 19/4885 |
| US-20210371449-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885ADORA3 35/4885ADORA2A 19/4885 |
| US-20200222441-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ENTPD5, NT5C2, ENTPD1 | NT5E 4/4885ADORA3 34/4885ADORA2A 19/4885 |
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | NT5E 5/4885ADORA3 9/4885ADORA2A 8/4885 |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885ADORA3 37/4885ADORA2A 19/4885 |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885ADORA3 37/4885ADORA2A 19/4885 |
| US-20200062797-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 28/4885ADORA2A 13/4885 |
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885ADORA3 28/4885ADORA2A 13/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885ADORA3 29/4885ADORA2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.